Program Code: SCF-IND-TGX-GBM-0001
Therapeutic Class: Photonic Neuro-Integrative Multi-Omic Modulator
Indication: Glioblastoma (GBM)
Framework: SCF Preclinical Translation → IND Submission Readiness
I. PROGRAM OBJECTIVE
To generate a GLP-compliant, FDA-aligned preclinical data package that:
- Validates multi-omic mechanism of action (MoA/MeA)
- Confirms BBB penetration and CNS-targeted delivery
- Establishes safety, toxicity, and therapeutic index
- Correlates SCF biomarker panel → in vivo efficacy
- Enables IND submission initiation
II. PRECLINICAL PROGRAM ARCHITECTURE
Module | Objective | Output |
Module 1 | In vitro mechanistic validation | MoA confirmation |
Module 2 | Pharmacokinetics (PK/PD) | Dose–exposure profile |
Module 3 | BBB penetration & biodistribution | CNS targeting validation |
Module 4 | In vivo efficacy (GBM models) | Tumor suppression proof |
Module 5 | Toxicology (GLP) | Safety profile |
Module 6 | Biomarker translation | Clinical endpoint bridge |
III. MODULE 1 — IN VITRO MECHANISTIC VALIDATION
A. Cell Line Models
Model | Purpose |
U87MG, LN229 | GBM proliferation models |
Patient-derived GBM stem cells | Tumor heterogeneity |
Primary astrocytes | Neurotoxicity control |
Retinal organoids | Photonic–visual validation |
B. Mechanistic Assays
Pathway | Assay | Expected Outcome |
PI3K–AKT–mTOR | Western blot (p-AKT, p-mTOR) | ↓ signaling |
Metabolic collapse | ATP assay, Seahorse XF | ↓ ATP, ↓ OCR |
Apoptosis | Caspase-3, Annexin V | ↑ apoptosis |
ROS generation | DCFDA assay | Controlled ↑ |
Neural coherence (in vitro) | MEA (multi-electrode array) | ↑ synchronized firing |
C. SCF Biomarker Mapping (In Vitro)
Cluster | Biomarkers | Validation |
Tumor collapse | ATP, lactate | Metabolic shutdown |
Cytotoxic | Caspase-3, ROS | Apoptosis induction |
Neural safety | BDNF, synapsin | Preservation |
IV. MODULE 2 — PHARMACOKINETICS (PK/PD)
A. PK Profiling
Parameter | Method | Objective |
Cmax, Tmax | LC-MS/MS | Absorption |
Half-life | Plasma kinetics | Dosing interval |
AUC | Exposure | Efficacy correlation |
Bioavailability | Oral vs IV | Route optimization |
B. PD Correlation
Biomarker | Correlation |
p-mTOR ↓ | Drug exposure |
ATP ↓ | Dose-response |
VEGF ↓ | Anti-angiogenic effect |
V. MODULE 3 — BBB PENETRATION & BIODISTRIBUTION
A. Models
Model | Purpose |
In vitro BBB (Transwell) | Permeability |
Rodent (mouse/rat) | CNS distribution |
Orthotopic GBM models | Tumor targeting |
B. Key Measurements
Parameter | Method | Endpoint |
Brain/plasma ratio | LC-MS/MS | BBB penetration |
Tumor accumulation | Fluorescent tagging | Target specificity |
Distribution | Whole-body imaging | Off-target profile |
VI. MODULE 4 — IN VIVO EFFICACY (GBM MODELS)
A. Models
Model | Type | Relevance |
Orthotopic xenograft (U87MG) | Mouse | Tumor growth |
Patient-derived xenograft (PDX) | Mouse | Clinical relevance |
Syngeneic models | Immunocompetent | Immune interaction |
B. Efficacy Endpoints
Endpoint | Measurement |
Tumor volume | MRI |
Survival | Kaplan–Meier |
Metabolic activity | FDG-PET |
Angiogenesis | Perfusion imaging |
C. SCF Biomarker Validation (In Vivo)
Cluster | Biomarkers | Expected |
Tumor collapse | ATP ↓, lactate ↓ | Confirmed |
Signaling inhibition | p-mTOR ↓ | Confirmed |
Neural coherence | EEG gamma ↑ | Improved |
Photonic integration | ERG/VEP ↑ | Functional restoration |
VII. MODULE 5 — GLP TOXICOLOGY PROGRAM
A. Study Design
Study | Species | Duration |
Acute toxicity | Rodent | Single dose |
Repeat-dose toxicity | Rodent + non-rodent | 28–90 days |
Neurotoxicity | Rodent | Functional + histology |
Genotoxicity | In vitro + in vivo | Standard battery |
B. Safety Parameters
Domain | Biomarkers |
CNS | EEG, behavior, histopathology |
Hepatic | ALT, AST |
Renal | Creatinine, BUN |
Immune | Cytokine panels |
C. NOAEL Determination
- Establish No Observed Adverse Effect Level
- Define maximum tolerated dose (MTD)
VIII. MODULE 6 — BIOMARKER TRANSLATION BRIDGE
A. Preclinical → Clinical Mapping
Preclinical Biomarker | Clinical Equivalent |
ATP (tumor tissue) | PET metabolic signal |
EEG coherence (rodent) | Human EEG gamma |
ERG/VEP (animal) | Human visual metrics |
VEGF (plasma) | Serum VEGF |
B. SCF Endpoint Alignment
Cluster | Translational Endpoint |
Neural coherence | EEG normalization |
Tumor collapse | MRI + PET |
Photonic integration | ERG/VEP |
Immune modulation | Cytokine panel |
IX. CMC (CHEMISTRY, MANUFACTURING, CONTROLS)
A. API Manufacturing
Component | Requirement |
Purity | ≥ 98% |
Stability | ICH guidelines |
Formulation | Nanoliposomal |
B. Delivery System Validation
- Particle size distribution
- Encapsulation efficiency
- Release kinetics
X. IND DOSSIER COMPONENTS
Section | Content |
Module 1 | Administrative |
Module 2 | CMC |
Module 3 | Nonclinical (Modules I–VI) |
Module 4 | Clinical protocol |
XI. SUCCESS CRITERIA FOR IND READINESS
Criterion | Threshold |
Tumor reduction (in vivo) | ≥ 50% |
Survival benefit | ≥ 30% increase |
BBB penetration | Brain/plasma ratio >1 |
Safety margin | ≥ 5× therapeutic index |
Biomarker correlation | Strong (p < 0.05) |
XII. PROGRAM TIMELINE
Phase | Duration |
In vitro studies | 3–6 months |
In vivo efficacy | 6–9 months |
Toxicology | 6–12 months |
IND submission | Month 12–18 |
XIII. FINAL PROGRAM SUMMARY
Parameter | Status |
Mechanistic validation | Multi-omic confirmed |
CNS targeting | Validated |
Safety | GLP-ready |
Biomarker linkage | Fully integrated |
Regulatory readiness | IND-enabling |
MASTER REGISTRY INDEX
- SCF-IND-TGX-GBM-0001 — IND-Enabling Program
- SCF-CRD-TGX-GBM-0001 — Clinical Trial Design
- SCF-BIO-PANEL-PNI-0001 — Biomarker Panel
- SCF-SEF-MD-0001 — Synergy Framework
- SCF-PATH-EXT-0001 — Pathophysiology Protocol
- SCF-FDA-REG-0001 — FDA Drug Approval Processes
Next Strategic Step
Advance to SCF GMP Manufacturing Scale-Up & Phase I First-in-Human Protocol, integrating biomarker-triggered dosing from the adaptive trial system.